ecancermedicalscience

Review

Treatment plan for breast cancer with sentinel node metastasis

8 Jan 2014
Efrén Bolívar Abreu, Pedro Martinez, Luis Betancourt, Gabriel Romero, Ali Godoy, Laura Bergamo

Lymph node involvement is considered to be one of the most important independent prognostic factors in breast cancer. In patients without palpable lymphadenopathies, the method of choice for determining this involvement is the sentinel lymph node biopsy. In the presence of macrometastases, the current standard is to perform axillary lymph node dissection in spite of the knowledge that the involvement of non-sentinel lymph nodes is approximately 50%. When lymph node involvement is micrometastasic, the decision as to whether or not to proceed with lymphadenectomy remains in dispute. We set out, on the basis of the current scientific evidence and our own experience, to create guidelines that allow us to individualise each case and decide whether or not to perform a lymphadenectomy. We will discuss the arguments that support our position.

Related Articles

Arunah Chandran, Ishu Kataria, Kunal Oswal, Rita Isaac, Meritxell Mallafré-Larrosa, Sathishrajaa Palaniraja, Rajaraman Swaminathan, Rohit Rebello, Nandimandalam Venkata Vani, Bindhya Vijayan, Moni Kuriakose, Arnie Purushotham, Rengaswamy Sankaranarayanan, Jerard Selvam, Richard Sullivan, Partha Basu
Chalothorn Wannaphut, Phuuwadith Wattanachayakul, Sakditad Saowapa, Ben Ponvilawan, Manasawee Tanariyakul, Jakrin Kewcharoen, Pitchaporn Yingchoncharoen, Thanathip Suenghataiphorn, Noppawit Aiumtrakul, Jared Acoba
Fatuma Affey, Dabo Galgalo Halake, Grace Muira Wainaina, Hussein Ali Osman, James G Ndukui, Houda Abdourahman, Omar Abdihamid
Carl Arenos, Steven Lim, Andreu Lominoque, Isabela Reveldez, Angeli Sison-Dimaano, Nehar Pagandaman, Vincent Tatoy, Timothy Uy, Michael San Juan